Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030584583> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2030584583 endingPage "128" @default.
- W2030584583 startingPage "126" @default.
- W2030584583 abstract "Introduction Over the past 60 years, clinicians have used vitamin K antagonists, primarily warfarin, as the sole oral anticoagulants for managing a variety of thrombotic disorders. Warfarin, which requires frequent monitoring, has a variable dose response, a narrow therapeutic index, and numerous drug and dietary interactions. However, intravenous and subcutaneous agents, such as unfractionated heparin, low-molecular-weight heparin, direct thrombin inhibitors, and pentasaccharide, have been introduced over the past 30 years for managing thromboembolic disorders. Recently, 5 new oral anticoagulants, dabigatran, rivaroxaban, apixaban, endoxaban, and betrixaban, have been introduced into clinical trials. Apixaban, rivaroxaban, endoxaban, and betrixaban are specific direct inhibitors of factor Xa, while dabigatran inhibits factor IIa. These drugs have a pharmacological profile that does not require monitoring in order to adjust therapy, which is the mainstay of warfarin management. In addition, these new medications have not shown any major issues regarding food interactions; rather, they demonstrate the potential for limited drug-drug interactions due to their limited metabolism through the cytochrome P450 system. This unique pharmacokinetic profile may provide clinicians with a new era of managing thromboembolic disorders. Two of these agents, dabigatran and rivaroxaban, have been approved by the US Food and Drug Administration (FDA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF); in addition, rivaroxaban can be used in the prevention of venous thromboembolism (VTE) in total hip and knee arthroplasty during the acute and extended periods of risk. However, the challenge for hospital formularies will be the appropriate use and management of these new medications as they become integrated into outpatient care. In order to better understand the issues that pharmacy and therapeutics committees will encounter, a review of the 2 FDA-approved oral anticoagulants will be evaluated." @default.
- W2030584583 created "2016-06-24" @default.
- W2030584583 creator A5057266440 @default.
- W2030584583 date "2012-08-01" @default.
- W2030584583 modified "2023-10-17" @default.
- W2030584583 title "The New Oral Anticoagulants: A Challenge for Hospital Formularies" @default.
- W2030584583 cites W2014491911 @default.
- W2030584583 cites W2036506340 @default.
- W2030584583 cites W2097854437 @default.
- W2030584583 cites W2112275236 @default.
- W2030584583 cites W2136489990 @default.
- W2030584583 cites W2150567120 @default.
- W2030584583 cites W2151252098 @default.
- W2030584583 doi "https://doi.org/10.3810/hp.2012.08.996" @default.
- W2030584583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23086101" @default.
- W2030584583 hasPublicationYear "2012" @default.
- W2030584583 type Work @default.
- W2030584583 sameAs 2030584583 @default.
- W2030584583 citedByCount "1" @default.
- W2030584583 countsByYear W20305845832016 @default.
- W2030584583 crossrefType "journal-article" @default.
- W2030584583 hasAuthorship W2030584583A5057266440 @default.
- W2030584583 hasConcept C100406419 @default.
- W2030584583 hasConcept C126322002 @default.
- W2030584583 hasConcept C177713679 @default.
- W2030584583 hasConcept C2776301958 @default.
- W2030584583 hasConcept C2777292125 @default.
- W2030584583 hasConcept C2778661090 @default.
- W2030584583 hasConcept C2778810321 @default.
- W2030584583 hasConcept C2779161974 @default.
- W2030584583 hasConcept C2780290652 @default.
- W2030584583 hasConcept C2780638905 @default.
- W2030584583 hasConcept C57002609 @default.
- W2030584583 hasConcept C71924100 @default.
- W2030584583 hasConcept C89560881 @default.
- W2030584583 hasConcept C98274493 @default.
- W2030584583 hasConceptScore W2030584583C100406419 @default.
- W2030584583 hasConceptScore W2030584583C126322002 @default.
- W2030584583 hasConceptScore W2030584583C177713679 @default.
- W2030584583 hasConceptScore W2030584583C2776301958 @default.
- W2030584583 hasConceptScore W2030584583C2777292125 @default.
- W2030584583 hasConceptScore W2030584583C2778661090 @default.
- W2030584583 hasConceptScore W2030584583C2778810321 @default.
- W2030584583 hasConceptScore W2030584583C2779161974 @default.
- W2030584583 hasConceptScore W2030584583C2780290652 @default.
- W2030584583 hasConceptScore W2030584583C2780638905 @default.
- W2030584583 hasConceptScore W2030584583C57002609 @default.
- W2030584583 hasConceptScore W2030584583C71924100 @default.
- W2030584583 hasConceptScore W2030584583C89560881 @default.
- W2030584583 hasConceptScore W2030584583C98274493 @default.
- W2030584583 hasIssue "3" @default.
- W2030584583 hasLocation W20305845831 @default.
- W2030584583 hasLocation W20305845832 @default.
- W2030584583 hasOpenAccess W2030584583 @default.
- W2030584583 hasPrimaryLocation W20305845831 @default.
- W2030584583 hasRelatedWork W129456579 @default.
- W2030584583 hasRelatedWork W1743249904 @default.
- W2030584583 hasRelatedWork W1998974240 @default.
- W2030584583 hasRelatedWork W2030584583 @default.
- W2030584583 hasRelatedWork W2126328654 @default.
- W2030584583 hasRelatedWork W2186954303 @default.
- W2030584583 hasRelatedWork W2286397275 @default.
- W2030584583 hasRelatedWork W2530598496 @default.
- W2030584583 hasRelatedWork W2804281431 @default.
- W2030584583 hasRelatedWork W3194483582 @default.
- W2030584583 hasVolume "40" @default.
- W2030584583 isParatext "false" @default.
- W2030584583 isRetracted "false" @default.
- W2030584583 magId "2030584583" @default.
- W2030584583 workType "article" @default.